A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2002
10/10/2002	WO2002078683A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	WO2002078671A1 Medical aerosol formulations
10/10/2002	WO2002078669A1 Medicinal solutions
10/10/2002	WO2002078648A2 Topical composition comprising an antifungal
10/10/2002	WO2002078638A2 Morpholino imaging and therapy
10/10/2002	WO2002078623A2 Uses of targeted oxidative therapeutic formulation in arteriosclerosis
10/10/2002	WO2002078622A2 Targeted oxidative therapeutic formulation
10/10/2002	WO2002078605A2 Premixed amiodarone parenteral solution and method for making the same
10/10/2002	WO2002078602A2 Transdermal delivery of pergolide
10/10/2002	WO2002078600A2 γεRACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA
10/10/2002	WO2002078598A2 Peptides and antibodies to muc 1 proteins
10/10/2002	WO2002078580A1 Condom with an erectogenic composition
10/10/2002	WO2002078445A1 Formulations comprising entrapped active ingredients and uses thereof
10/10/2002	WO2002058749A3 Carrier with solid fibrinogen and solid thrombin
10/10/2002	WO2002051460A3 Bioactive materials for aneurysm repair
10/10/2002	WO2002051390A3 Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
10/10/2002	WO2002051386A3 Lipid microparticles by cryogenic micronization
10/10/2002	WO2002047725A3 Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
10/10/2002	WO2002041881A3 Repinotan kit
10/10/2002	WO2002039983A3 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
10/10/2002	WO2002039952A3 Synergistic ecta compositions
10/10/2002	WO2002034763A3 Mucin comprising vehicle for the transport of biologically-active agents
10/10/2002	WO2002034240A3 Delayed and sustained release formulations and method of use thereof
10/10/2002	WO2002032406A3 Methods and products related to pulmonary delivery of polysaccharides
10/10/2002	WO2002030472A3 Compositions for release of radiosensitizers, and methods of making and using the same
10/10/2002	WO2002030463A3 Reduced-viscosity concentrated protein formulations
10/10/2002	WO2002007739A3 Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma
10/10/2002	WO2002005747A3 The process of manufacturing pharmaceutical grade tannates
10/10/2002	WO2001096590A3 Deesterified pectins, processes for producing such pectins, and stabilized acidic liquid systems comprising the same
10/10/2002	WO2001078787A3 Lipopolysaccharide-conjugate vaccine for sepsis treatment
10/10/2002	WO2001074382A9 Method of treatment using ligand-immunogen conjugates
10/10/2002	WO2001053324A8 Novel haptotactic peptides
10/10/2002	US20020147311 Fusion protein for use in the treatment of tumors
10/10/2002	US20020147265 Ethylene-propylene-diene terpolymer blend
10/10/2002	US20020147239 Esmolol formulation
10/10/2002	US20020147236 Controlling concentration; side effect reduction
10/10/2002	US20020147232 Pharmaceutical compositions comprising desglymidodrine as an active drug substance
10/10/2002	US20020147223 Agent for enhancing accumulation of drugs in tumor tissues
10/10/2002	US20020147211 Synergistic mixture of angiotensin inhibitors, boric acid, ethylenediaminetetraacetic acid and active drug
10/10/2002	US20020147201 Glycyrrhizin complex
10/10/2002	US20020147180 Stable amorphous amifostine compositions and methods for the preparation of same
10/10/2002	US20020147177 Complexing with cyclodextrins; water solubility
10/10/2002	US20020147176 Thermoplastic and water-soluble cellulose ether esters
10/10/2002	US20020147175 Antiproliferative agents; anticancer agents; enzyme catalyzed therapy activation
10/10/2002	US20020147162 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)
10/10/2002	US20020147156 Cellular uptake of bioactive agents
10/10/2002	US20020147150 Sustained-release preparation
10/10/2002	US20020147138 Anticancer agents
10/10/2002	US20020147137 Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid
10/10/2002	US20020147136 Tetrapeptide
10/10/2002	US20020147133 Bifunctional molecules and therapies based thereon
10/10/2002	US20020147131 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue
10/10/2002	US20020146830 Methods and compositions for delivery of pharmaceutical agents
10/10/2002	US20020146829 Generating neutral or anionic complexes for gene transfer; form stable colloid, insert nucleotide sequence complex, adjust surface of complex to support colloid
10/10/2002	US20020146826 Cationic polysaccharide compositions
10/10/2002	US20020146802 Methods for producing and purifying recombinant alpha-L-iduronidase
10/10/2002	US20020146750 Mucin for use in the diagnosiss and treatment of cancer
10/10/2002	US20020146749 Diagnosis and treatment of neuroectodermal tumors
10/10/2002	US20020146504 Ternary biomolecule/polymer/surface-based immobilization systems
10/10/2002	US20020146466 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/10/2002	US20020146461 Combining phase comprising wherein active agent, polymer, solvent and second phase; flowing emulsion through static mixers; combining outflow with extraction liquid for extracting solvent from emulsion to form microparticles
10/10/2002	US20020146457 Preparing phase comprising a polymer, a psychotherapeutic agent, and solvent; preparing an aqueous phase and combining with first pahse to form emulsion; separation; reducing solvent in discontinuous phase
10/10/2002	US20020146456 Preparation of microparticles having improved flowability
10/10/2002	US20020146455 Shelf-life; caking and sedimentation are inhibited
10/10/2002	US20020146453 For sustained release; therapy
10/10/2002	US20020146451 Method for the administration of acid-labile drugs
10/10/2002	US20020146450 Liposome-entrapped topoisomerase inhibitors
10/10/2002	US20020146448 B-glucans encapsulated in liposomes
10/10/2002	US20020146426 Administering molecule joined to a heat shock protein or molecule joined to an adenosinetriphosphate (ATP) binding domain of a heat shock protein inducing an immune response that includes a CD8+ cytotoxic T lymphocyte (CTL) response
10/10/2002	US20020146414 Controlled release of non heparin-binding growth factors from heparin-containing matrices
10/10/2002	US20020146409 Providing a blood protein solution; adding hydroxypropyl-alpha -cyclodextrin in to form a stable complex with the protein; lyophilizing the solution of step to form a lyophilized protein/hydroxypropyl- alpha -cyclodextrin complex
10/10/2002	US20020146388 Cytokine immunoconjugates
10/10/2002	US20020146386 In vivo use of water absorbent polymers
10/10/2002	US20020146384 Exhibiting constant release rate and delayed release profiles
10/10/2002	US20020146370 Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
10/10/2002	US20020146369 Intraoperative, intravascular and endoscopic tumor and lesion detection, biopsy and therapy
10/10/2002	DE10117676A1 Pesticidal composition, useful for controlling fleas and ticks on animals, contains permethrin and imidacloprid, in N-methylpyrrolidone
10/10/2002	DE10117208A1 Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen A process for preparing low-viscosity, aqueous cellulose ether solutions
10/10/2002	DE10114247A1 Antibiotikum-/Antibiotika-Polymer-Kombination Antibiotic / polymer combination
10/10/2002	DE10114178A1 Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität Zinc-free and low-zinc insulin preparations with improved stability
10/10/2002	DE10102007A1 Tensidgemisch Surfactant mixture
10/10/2002	CA2443128A1 Transdermal delivery of pergolide
10/10/2002	CA2442531A1 Peptides and antibodies to muc 1 proteins
10/10/2002	CA2442486A1 Novel chocolate composition as delivery system for nutrients and medications
10/10/2002	CA2442365A1 Premixed amiodarone parenteral solution and method for making the same
10/10/2002	CA2442363A1 Reducing the immunogenicity of fusion proteins
10/10/2002	CA2442146A1 Formulations comprising entrapped active ingredients and uses thereof
10/10/2002	CA2442020A1 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/10/2002	CA2441970A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	CA2438083A1 Polymerized hydrogel adhesive
10/10/2002	CA2437996A1 Skin-compatible hydrogel adhesives
10/10/2002	CA2437789A1 Topical composition comprising an antifungal
10/10/2002	CA2429108A1 .psi..epsilon.rack peptide composition and method for protection against tissue damage due to ischemia
10/09/2002	EP1247526A1 Perfusion liquid preparations for ophthalmic operations
10/09/2002	EP1247524A1 Composition comprising taurolidine and/or taurultam for the treatment of cancer
10/09/2002	EP1247522A1 Polyetherester copolymers as drug delivery matricess
10/09/2002	EP1247456A2 Palatable pharmaceutical compositions for companion animals
10/09/2002	EP1246931A1 Compositions comprising nucleic acids incorporated in bilaminar mineral particles
10/09/2002	EP1246830A1 Macrocyclic chelants for metallopharmaceuticals
10/09/2002	EP1246792A1 Compounds and compositions for delivering active agents

1 ... 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 ... 1712